Literature DB >> 15322218

C protein-induced myocarditis and subsequent dilated cardiomyopathy: rescue from death and prevention of dilated cardiomyopathy by chemokine receptor DNA therapy.

Yoh Matsumoto1, Yukiko Tsukada, Akira Miyakoshi, Hiroshi Sakuma, Kuniko Kohyama.   

Abstract

Severe experimental autoimmune myocarditis and subsequent dilated cardiomyopathy (DCM) were successfully produced in Lewis rats by immunization with recombinant cardiac C protein. Seventy-five percent of immunized rats died between days 15 and 49 postimmunization, and all of the survived rats showed typical DCM characterized by the presence of ventricular dilatation and extensive fibrosis. Immunopathological and chemokine analysis during the acute phase revealed that there were marked macrophage infiltration with myocyte necrosis and up-regulation of MCP-1 and IFN-gamma-inducible protein-10 (IP-10). Based on these findings, we prepared plasmid DNAs encoding the binding site of CCR2 and CXCR3, which are receptors for MCP-1 and IP-10, respectively. The culture supernatant of cells transfected with these DNAs inhibited the migration of T cells and macrophages induced by MCP-1 and IP-10. Remarkably, administration of the DNAs to C protein-immunized rats prevented the disease progression and rescued animals from death. The present study has demonstrated for the first time that gene therapy targeting the chemokine receptor could be a powerful tool for the control of experimental autoimmune myocarditis and DCM.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15322218     DOI: 10.4049/jimmunol.173.5.3535

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  B-cell epitope spreading is a critical step for the switch from C-protein-induced myocarditis to dilated cardiomyopathy.

Authors:  Yoh Matsumoto; Il-Kwon Park; Kuniko Kohyama
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 2.  Role of various proteases in cardiac remodeling and progression of heart failure.

Authors:  Alison L Müller; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

3.  Recombinant cardiac myosin fragment induces experimental autoimmune myocarditis via activation of Th1 and Th17 immunity.

Authors:  Melvin D Daniels; Kenneth V Hyland; Kegiang Wang; David M Engman
Journal:  Autoimmunity       Date:  2008-09       Impact factor: 2.815

Review 4.  Chagas heart disease pathogenesis: one mechanism or many?

Authors:  Kevin M Bonney; David M Engman
Journal:  Curr Mol Med       Date:  2008-09       Impact factor: 2.222

5.  Cardiac Myosin Binding Protein-C Autoantibodies are Potential Early Indicators of Cardiac Dysfunction and Patient Outcome in Acute Coronary Syndrome.

Authors:  Thomas L Lynch; Diederik W D Kuster; Beverly Gonzalez; Neelam Balasubramanian; Nandini Nair; Sharlene Day; Jenna E Calvino; Yanli Tan; Christoph Liebetrau; Christian Troidl; Christian W Hamm; Ahmet Güçlü; Barbara McDonough; Ali J Marian; Jolanda van der Velden; Christine E Seidman; Gordon S Huggins; Sakthivel Sadayappan
Journal:  JACC Basic Transl Sci       Date:  2016-12-19

6.  QiShenYiQi pill improves the reparative myocardial fibrosis by regulating autophagy.

Authors:  Shichao Lv; Peng Yuan; Jianping Dong; Chunmiao Lu; Meng Li; Fan Qu; Yaping Zhu; Zhuo Yuan; Junping Zhang
Journal:  J Cell Mol Med       Date:  2020-09-02       Impact factor: 5.310

7.  Fractalkine depresses cardiomyocyte contractility.

Authors:  David Taube; Jiang Xu; Xiao-Ping Yang; Albertas Undrovinas; Edward Peterson; Pamela Harding
Journal:  PLoS One       Date:  2013-07-30       Impact factor: 3.240

Review 8.  Surviving the infarct: A profile of cardiac myosin binding protein-C pathogenicity, diagnostic utility, and proteomics in the ischemic myocardium.

Authors:  Thomas L Lynch; Sakthivel Sadayappan
Journal:  Proteomics Clin Appl       Date:  2014-07-14       Impact factor: 3.494

9.  Effect and Mechanism of QiShenYiQi Pill on Experimental Autoimmune Myocarditis Rats.

Authors:  Shichao Lv; Meifang Wu; Meng Li; Qiang Wang; Ling Xu; Xiaojing Wang; Junping Zhang
Journal:  Med Sci Monit       Date:  2016-03-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.